BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28950655)

  • 21. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
    Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
    Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
    Levitzki A
    Annu Rev Pharmacol Toxicol; 2013; 53():161-85. PubMed ID: 23043437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Angiogenesis in Colorectal Cancer: Tyrosine Kinase Inhibitors.
    Kircher SM; Nimeiri HS; Benson AB
    Cancer J; 2016; 22(3):182-9. PubMed ID: 27341596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.
    Liu J; Sheng Z; Zhang Y; Li G
    Target Oncol; 2016 Feb; 11(1):49-58. PubMed ID: 26206590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer.
    Grávalos C; Cassinello J; Fernández-Rañada I; Holgado E
    Clin Colorectal Cancer; 2007 Nov; 6(10):691-9. PubMed ID: 18039422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials.
    Li G; Gao S; Sheng Z; Li B
    Chemotherapy; 2016; 61(4):179-89. PubMed ID: 26859739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
    Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
    Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.
    Koo DH; Kim KP; Choi CM; Lee DH; Lee JC; Lee JS; Jang SJ; Kim SW
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):197-206. PubMed ID: 25422153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
    Burotto M; Ali SA; O'Sullivan Coyne G
    Expert Opin Drug Saf; 2015 Jan; 14(1):97-110. PubMed ID: 25345687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.
    Ni J; Zhang L
    Chin Med J (Engl); 2016 Feb; 129(3):332-40. PubMed ID: 26831237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Future of Targeting FLT3 Activation in AML.
    Leick MB; Levis MJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.
    Lee CC; Shiao HY; Wang WC; Hsieh HP
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1333-48. PubMed ID: 24921970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.
    Luo S; Chen L; Chen X; Xie X
    Oncotarget; 2015 Jun; 6(18):16725-34. PubMed ID: 26057469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
    Manson GV; Ma PC
    Clin Lung Cancer; 2010 Jan; 11(1):57-60. PubMed ID: 20085869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiotoxicity induced by tyrosine kinase inhibitors.
    Orphanos GS; Ioannidis GN; Ardavanis AG
    Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
    Firwana B; Sonbol MB; Diab M; Raza S; Hasan R; Yousef I; Zarzour A; Garipalli A; Doll D; Murad MH; Al-Kali A
    Int J Cancer; 2016 Mar; 138(6):1545-53. PubMed ID: 26455714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
    DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review.
    Ranieri G; Pantaleo M; Piccinno M; Roncetti M; Mutinati M; Marech I; Patruno R; Rizzo A; Sciorsci RL
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):293-308. PubMed ID: 23768779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: A narrative review.
    Boskabadi SJ; Dashti A; Karevan S; Kargar-Soleimanabad S; Salehifar E
    J Oncol Pharm Pract; 2023 May; ():10781552231174790. PubMed ID: 37170573
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.